Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis additional cost-effectiveness analyses
07 March 2013
(120.38 Kb 35 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013